Pfizer is planning to test a daily weight-loss pill in mid-stage trials later this year, as the struggling pharmaceutical group pins its hope on the experimental drug as its route into a market projected to be worth more than $130bn a year.
辉瑞(Pfizer)正计划在今年晚些时候对一种日用减肥药进行中期试验，这家陷入困境的制药集团寄希望于将这种试验性药物作为其进入一个预计每年价值超过1300亿美元的市场的途径。
您已阅读8%（327字），剩余92%（3800字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。